TrialNature medicine2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
45 papers cite it
this paperpooled itcites it